Cagrilintide/semaglutide
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Novo Nordisk · Phase 3 · Withdrawn · Enrollment 0
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| CagriSema B in device 2 + Placebo in device 1 | n/r | n/r | n/r | n/r |
| CagriSema in device 1 + Placebo in device 2 | n/r | n/r | n/r | n/r |
| Placebo in device 1 + Placebo in device 2 | n/r | n/r | n/r | n/r |
Not shown
- CagriSema B in device 2 + Placebo in device 1: endpoint not reported
- CagriSema in device 1 + Placebo in device 2: endpoint not reported
- Placebo in device 1 + Placebo in device 2: endpoint not reported